During the past decade, Hospital de Base de Sao Jose do Rio Preto conducted 71 clinical trials. In the 10-year time frame, 71 clinical trials started and 25 clinical trials were completed, i.e. on average, 35.2% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 21 clinical trials were completed. i.e. 47.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital de Base de Sao Jose do Rio Preto" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Janssen Research & Development, LLC" with 12 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital de Base de Sao Jose do Rio Preto" #1 collaborator was "AstraZeneca" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Ministry of Health, Brazil" with 2 trials as a collaborator and "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Hospital de Base de Sao Jose do Rio Preto" are "Prostatic Neoplasms" (4 trials), "Breast Cancer" (3 trials), "COVID-19" (3 trials), "Metastatic Breast Cancer" (3 trials) and "Acute Myeloid Leukemia" (2 trials). Many other conditions were trialed in "Hospital de Base de Sao Jose do Rio Preto" in a lesser frequency.

Most popular intervention types in "Hospital de Base de Sao Jose do Rio Preto" are "Drug" (69 trials), "Biological" (11 trials), "Other" (9 trials), "Device" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Atezolizumab" (5 trials), "Carboplatin" (4 trials), "Paclitaxel" (4 trials) and "Pembrolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hospital de Base de Sao Jose do Rio Preto" are 71 trials for "All" genders, 4 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital de Base de Sao Jose do Rio Preto". undefined are not yet recruiting, 22 are recruiting, 26 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Hospital de Base de Sao Jose do Rio Preto, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital de Base de Sao Jose do Rio Preto, 4 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".